JACC:马拉松训练可以逆转年龄引起的血管硬化

2020-01-11 不详 MedSci原创

年龄会增加主动脉的硬度,从而增加健康人群心血管疾病的风险。本研究的目的旨在评估第一次的马拉松训练是否能逆转年龄带来的主动脉硬度变化。本研究对未受过锻炼的健康人群进行了6个月的马拉松训练,训练前和马拉松后2周的评估包括中心(主动脉)血压和主动脉硬度。最终,共纳入分析了138名第一次参加马拉松的对象(21-69岁,男性占49%),平均每周的训练计划为6-13英里。在基线水平,10年的老化时间分别与升主

年龄会增加主动脉的硬度,从而增加健康人群心血管疾病的风险。本研究的目的旨在评估第一次的马拉松训练是否能逆转年龄带来的主动脉硬度变化。

本研究对未受过锻炼的健康人群进行了6个月的马拉松训练,训练前和马拉松后2周的评估包括中心(主动脉)血压和主动脉硬度。最终,共纳入分析了138名第一次参加马拉松的对象(21-69岁,男性占49%),平均每周的训练计划为6-13英里。在基线水平,10年的老化时间分别与升主动脉、降主动脉肺动脉分叉段和降主动脉膈段扩张性的减少2.3、1.9和 3.1 × 10-3 mm Hg-1(p < 0.05)呈相关性。马拉松训练可以减少4mmHg主动脉收缩压和3mmHg舒张压。降主动脉的扩张性有所升高,但升主动脉无明显变化,这意味着降主动脉肺动脉分叉段和降主动脉膈段的"血管年龄"分别年轻了3.9岁和4岁。另外,跑步时间较慢的老年男性参与者受益更大。

研究结果显示,即使很低强度的马拉松训练都可以降低主动脉血压和改善主动脉血管硬度。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691263, encodeId=698c1691263a1, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Wed Apr 15 21:32:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854629, encodeId=8618185462940, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Mar 18 07:32:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326456, encodeId=88221326456a0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428963, encodeId=36e314289633d, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378047, encodeId=bc003e80475c, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 11 21:54:06 CST 2020, time=2020-01-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1691263, encodeId=698c1691263a1, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Wed Apr 15 21:32:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854629, encodeId=8618185462940, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Mar 18 07:32:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326456, encodeId=88221326456a0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428963, encodeId=36e314289633d, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378047, encodeId=bc003e80475c, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 11 21:54:06 CST 2020, time=2020-01-11, status=1, ipAttribution=)]
    2020-03-18 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1691263, encodeId=698c1691263a1, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Wed Apr 15 21:32:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854629, encodeId=8618185462940, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Mar 18 07:32:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326456, encodeId=88221326456a0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428963, encodeId=36e314289633d, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378047, encodeId=bc003e80475c, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 11 21:54:06 CST 2020, time=2020-01-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1691263, encodeId=698c1691263a1, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Wed Apr 15 21:32:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854629, encodeId=8618185462940, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Mar 18 07:32:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326456, encodeId=88221326456a0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428963, encodeId=36e314289633d, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378047, encodeId=bc003e80475c, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 11 21:54:06 CST 2020, time=2020-01-11, status=1, ipAttribution=)]
    2020-01-13 zxl730
  5. [GetPortalCommentsPageByObjectIdResponse(id=1691263, encodeId=698c1691263a1, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Wed Apr 15 21:32:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854629, encodeId=8618185462940, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Mar 18 07:32:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326456, encodeId=88221326456a0, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428963, encodeId=36e314289633d, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Mon Jan 13 11:32:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378047, encodeId=bc003e80475c, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 11 21:54:06 CST 2020, time=2020-01-11, status=1, ipAttribution=)]
    2020-01-11 天地飞扬

    厉害了

    0

相关资讯

这个药审批通过,事关中国2.9亿不良心血管事件患者

近日,中国国家药品监督管理局(NMPA)正式批准阿利西尤单抗注射液(商品名:波立达®,Praluent®)用于动脉粥样硬化性心血管疾病患者的心血管事件预防以及原发性高胆固醇血症(杂合子型家族性和非家族性)和混合性血脂异常中降低低密度脂蛋白胆固醇水平的治疗。

JACC:舒张压和静息心率可预测主动脉反流患者死亡风险

本研究的目的旨在评估舒张压(DBP)和静息心率(RHR)与主动脉反流(AR)患者全因死亡率的相关性。本研究纳入分析了820名中重度AR患者(平均年龄59 ± 17岁,男性占82%),经过平均5.5 ± 3.5年时间的随访,有104名接受药物治疗的患者死亡,400名患者接受了主动脉瓣置换术(AVS)。年龄、临床症状、左室射血分数(LVEF)、左室收缩末期直径指数(LVESDi)、DBP和RHR均为全

Eur Heart J:高甘油三酯会增加动脉粥样硬化性心血管病患者的风险

REDUCE-IT临床试验结果显示乙醇酸盐可以改善动脉粥样硬化性心血管病(ASCVD)伴高甘油三酯血症患者的预后,在患有ASCVD的人群中,本研究试图量化与高甘油三酯血症相关的ASCVD事件。在ASCVD的患者中,本研究探究了甘油三酯(TG)和ASCVD事件(首次出现心肌梗死、不稳定心绞痛、中风或短暂缺血发作、冠状动脉血运重建或心血管死亡)之间的相关性。TG 135-499mg/dL(1.52-5

EHJ连发8文,总结2019年度心血管进展

2020年1月6日,欧洲心脏病杂志(European Heart Journal, EHJ)在线发表了《The year in cardiology 2019》系列文章,盘点了2019年心血管领域取得的重要进展。涉及到的领域包括:急性冠脉综合征、主动脉和外周循环、心律失常、心衰、心血管影像、冠脉介入、心血管疾病预防、心脏瓣膜病。平常没时间追踪进展?赶紧查看这些精彩总结,快速了解心血管领域最新进展吧

JACC:运动性肺动脉高压与呼吸困难患者不良预后相关

某些人会出现运动引起的肺动脉压(PAP)异常反应,然而,在更广泛的样本中,运动性肺动脉高压(exPH)的临床和预后意义尚不清楚。本研究纳入分析了在有创性血流动力学监测下进行心肺运动试验的慢性劳力性呼吸困难和保留射血分数的患者。运动性肺动脉高压通过逐分钟PAP和心输出量(CO)测量来确定PAP/CO斜率,exPH定义为PAP/CO斜率>3mm Hg/l/min。主要终点事件是心血管住院或全因死

JACC:室性早搏心肌病神经重塑的特点

室性早搏心肌病(PVC-CM)神经重塑的存在及其意义尚不清楚。本研究旨在探讨犬PVC-CM模型的心交感神经平衡和心律失常发生的特点。在本研究中,对12只犬植入心外膜起搏器和无线遥测装置,记录左星状神经节(SNA)、左心迷走神经(VNA)和动脉血压的心律和神经活动(NA),应用二联PVCs(200ms耦合)12周诱导7只动物形成PVC-CM,然后停用4周,使左室射血分数(LVEF)完全恢复,并与5只